- Home
- AOD vs REPL Comparison
AOD vs REPL Comparison
Compare AOD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOD
- REPL
- Stock Information
- Founded
- AOD 2006
- REPL 2015
- Country
- AOD United Kingdom
- REPL United States
- Employees
- AOD N/A
- REPL N/A
- Industry
- AOD Investment Managers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AOD Finance
- REPL Health Care
- Exchange
- AOD Nasdaq
- REPL Nasdaq
- Market Cap
- AOD 862.4M
- REPL 757.8M
- IPO Year
- AOD N/A
- REPL 2018
- Fundamental
- Price
- AOD $9.04
- REPL $12.24
- Analyst Decision
- AOD
- REPL Strong Buy
- Analyst Count
- AOD 0
- REPL 7
- Target Price
- AOD N/A
- REPL $21.00
- AVG Volume (30 Days)
- AOD 423.5K
- REPL 1.9M
- Earning Date
- AOD 01-01-0001
- REPL 08-07-2025
- Dividend Yield
- AOD 12.95%
- REPL N/A
- EPS Growth
- AOD 213.63
- REPL N/A
- EPS
- AOD 1.93
- REPL N/A
- Revenue
- AOD $72,962,082.00
- REPL N/A
- Revenue This Year
- AOD N/A
- REPL N/A
- Revenue Next Year
- AOD N/A
- REPL N/A
- P/E Ratio
- AOD $4.44
- REPL N/A
- Revenue Growth
- AOD N/A
- REPL N/A
- 52 Week Low
- AOD $6.99
- REPL $6.44
- 52 Week High
- AOD $9.14
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- AOD 66.00
- REPL 73.41
- Support Level
- AOD $8.88
- REPL $9.26
- Resistance Level
- AOD $9.00
- REPL $13.19
- Average True Range (ATR)
- AOD 0.06
- REPL 0.68
- MACD
- AOD -0.00
- REPL 0.29
- Stochastic Oscillator
- AOD 100.00
- REPL 80.10
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.